Utilización de anfotericina B no convencional en el Hospital Clínico de San Carlos
Background: Amphotericin B is the treatment of choice for systemic fungal infections, however, its clínica1 usefulness is limited by its toxicity. The lipid formulations appear to be equally effective and safer, but are more costly. The increase in the consumption of, and expenditure on these formul...
Saved in:
Published in | Revista española de salud pública Vol. 74; no. 4; pp. 351 - 359 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | Spanish English |
Published |
Ministerio de Sanidad y Consumo
2000
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Background: Amphotericin B is the treatment of
choice for systemic fungal infections, however, its clínica1
usefulness is limited by its toxicity. The lipid formulations
appear to be equally effective and safer, but are more
costly. The increase in the consumption of, and expenditure
on these formulas led us to undertake a study in order to
identify their profile of use (quantitative and qualitative)
and to assess the financia1 repercussions when used
inappropriately.
Methods: A set of rules were developed for the use of
amphotericin B, and the quality of the prescription of nonconventional
amphotericin B (amphotericin B notC) was
evaluated retrospectively together with the financia1
repercussions of its inappropriate use.
Results: In 54% of the treatments studied, a poor
selection of amphotericin B was made; in 3.5% the use of
amphotericin B was not indicated. The excess expenditure
derived from the inappropriate use amounted to 42 million
pesetas, 35% of the total expenditure on medicines; the
expenditure due to unnecessary prescription was 1,720,327
pesetas.
Conclusions: The retrospective evaluation has shown
that there is a high percentage of treatments that do not
conform with the recommendations contained in the
prescription rules. The holding of information sessions
would assist in achieving a more efficient selection of the
amphotericin B notC; this would improve prescription
quality, which might also deliver significant financia1
savings.
Fundamento: La anfotericina B es el tratamiento de
elección de las infecciones fúngicas sistémicas, pero su utilidad
clínica está limitada por su toxicidad. Las formulaciones
lipídicas parecen igualmente eficaces y más seguras,
pero tienen un mayor coste. El incremento del consumo y
del gasto de estas formulaciones nos llevo a plantear un
estudio para conocer su perfil de utilización (cuantitativo y
cualitativo) y evaluar la repercusión económica de su uso
inapropiado.
Utilisation of non-conventional
Amphotericin B in the San Carlos
Clinical Hospital
Métodos: Se desarrollaron unas normas de uso de la
anfotericina B y se evaluó de forma retrospectiva, la calidad
de la prescripción de la anfotericina B no convencional
(anfotericina B noC) y la repercusión económica de su uso
incorrecto.
Resultados: En el 54% de los tratamientos se hizo
una mala selección de anfotericina B; en el 3.5% no estaba
indicada la utilización de anfotericina B. El exceso de
gasto derivado de la prescripción incorrecta fue de 42
millones de pesetas, un 35% del gasto total en medicamentos;
el gasto por prescripción innecesaria fue de
1.720.327 pesetas.
Background: Amphotericin B is the treatment of
choice for systemic fungal infections, however, its clínica1
usefulness is limited by its toxicity. The lipid formulations
appear to be equally effective and safer, but are more
costly. The increase in the consumption of, and expenditure
on these formulas led us to undertake a study in order to
identify their profile of use (quantitative and qualitative)
and to assess the financia1 repercussions when used
inappropriately.
Methods: A set of rules were developed for the use of
amphotericin B, and the quality of the prescription of nonconventional
amphotericin B (amphotericin B notC) was
evaluated retrospectively together with the financia1
repercussions of its inappropriate use.
Conclusiones: La evaluación retrospectiva ha mostrado
que existe un elevado porcentaje de tratamientos que
no se adecuan a lo recomendado en las normas de prescripción.
La puesta en marcha de intervenciones informativas
permitiría realizar una selección más eficiente de la
anfotericina B noC, mejorando la calidad de la prescrip
ción, lo que podría suponer un importante ahorro económico.
Results: In 54% of the treatments studied, a poor
selection of amphotericin B was made; in 3.5% the use of
amphotericin B was not indicated. The excess expenditure
derived from the inappropriate use amounted to 42 million
pesetas, 35% of the total expenditure on medicines; the
expenditure due to unnecessary prescription was 1,720,327
pesetas. |
---|---|
ISSN: | 1135-5727 2173-9110 |